Beam Therapeutics Inc.
NASDAQBeam Therapeutics enters the second week of July with a sharp price rally colliding head-on with one of the heaviest short positions in the gene-editing space. The stock closed at $37.92 on Tuesday, up 10.5% on the week and 29% over the past month — a meaningful move for a pre-revenue biotech that spent much of the spring trading in the low-to-mid $20s. That recovery has not…
BEAM short interest surges 31% in one week to 28.6% of float, highest since late May, as clinical-stage gene editor faces mounting pressure from short sellers despite upcoming regulatory catalysts.
Snapshot as of 12 Aug 2026
Beam Therapeutics enters the second week of July with a sharp price rally colliding head-on with one of the heaviest short positions in the gene-editing space. The stock closed at $37.92 on Tuesday, up 10.5% on the…
Beam Therapeutics heads into mid-May with its short sellers in full retreat — and a string of data catalysts lined up that could test how far that retreat goes. Short interest has dropped sharply over the past three…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BEAM — free to start on ORTEX.
Sign up for free →Open BEAM on ORTEX